Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CLDN18.2 inhibitor
DRUG CLASS:
CLDN18.2 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
FL-301 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
FL-301 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
›
Associations
(30)
News
Trials
VERI cancer hierarchy
Reset Filters
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
zolbetuximab-clzb
Sensitive: A1 - Approval
Precision Medicine Online - 3 weeks (New A1)
zolbetuximab-clzb
Sensitive
:
A1
Precision Medicine Online - 3wk
zolbetuximab-clzb
Sensitive: A1 - Approval
Precision Medicine Online - 3 weeks
zolbetuximab-clzb
Sensitive
:
A1
Precision Medicine Online - 3 weeks - (New A1)
CLDN18.2 positive + HER-2 negative
Gastric Cancer
CLDN18.2 positive + HER-2 negative
Gastric Cancer
zolbetuximab-clzb
Sensitive: A1 - Approval
Precision Medicine Online - 3 weeks (New A1)
zolbetuximab-clzb
Sensitive
:
A1
Precision Medicine Online - 3wk
zolbetuximab-clzb
Sensitive: A1 - Approval
Precision Medicine Online - 3 weeks
zolbetuximab-clzb
Sensitive
:
A1
Precision Medicine Online - 3 weeks - (New A1)
CLDN18.2 expression + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 expression + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
zolbetuximab-clzb
Sensitive: B - Late Trials
zolbetuximab-clzb
Sensitive
:
B
zolbetuximab-clzb
Sensitive: B - Late Trials
zolbetuximab-clzb
Sensitive
:
B
CLDN18.2 expression + HER-2 negative
Gastric Cancer
CLDN18.2 expression + HER-2 negative
Gastric Cancer
zolbetuximab-clzb
Sensitive: B - Late Trials
zolbetuximab-clzb
Sensitive
:
B
zolbetuximab-clzb
Sensitive: B - Late Trials
zolbetuximab-clzb
Sensitive
:
B
CLDN18.2 expression
Esophageal Adenocarcinoma
CLDN18.2 expression
Esophageal Adenocarcinoma
zolbetuximab-clzb
Sensitive: C2 – Inclusion Criteria
zolbetuximab-clzb
Sensitive
:
C2
zolbetuximab-clzb
Sensitive: C2 – Inclusion Criteria
zolbetuximab-clzb
Sensitive
:
C2
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
zolbetuximab-clzb
Sensitive: C2 – Inclusion Criteria
zolbetuximab-clzb
Sensitive
:
C2
zolbetuximab-clzb
Sensitive: C2 – Inclusion Criteria
zolbetuximab-clzb
Sensitive
:
C2
CLDN18.2 expression
Gastric Adenocarcinoma
CLDN18.2 expression
Gastric Adenocarcinoma
zolbetuximab-clzb
Sensitive: C2 – Inclusion Criteria
zolbetuximab-clzb
Sensitive
:
C2
zolbetuximab-clzb
Sensitive: C2 – Inclusion Criteria
zolbetuximab-clzb
Sensitive
:
C2
CLDN18.2 positive
Solid Tumor
CLDN18.2 positive
Solid Tumor
MIL93
Sensitive: C2 – Inclusion Criteria
MIL93
Sensitive
:
C2
MIL93
Sensitive: C2 – Inclusion Criteria
MIL93
Sensitive
:
C2
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
AB011
Sensitive: C2 – Inclusion Criteria
AB011
Sensitive
:
C2
AB011
Sensitive: C2 – Inclusion Criteria
AB011
Sensitive
:
C2
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
ASP2138
Sensitive: C2 – Inclusion Criteria
ASP2138
Sensitive
:
C2
ASP2138
Sensitive: C2 – Inclusion Criteria
ASP2138
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
ASP2138
Sensitive: C2 – Inclusion Criteria
ASP2138
Sensitive
:
C2
ASP2138
Sensitive: C2 – Inclusion Criteria
ASP2138
Sensitive
:
C2
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
zolbetuximab-clzb
Sensitive: C2 – Inclusion Criteria
zolbetuximab-clzb
Sensitive
:
C2
zolbetuximab-clzb
Sensitive: C2 – Inclusion Criteria
zolbetuximab-clzb
Sensitive
:
C2
CLDN18.2 expression
Esophageal Cancer
CLDN18.2 expression
Esophageal Cancer
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
CLDN18.2 overexpression
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 overexpression
Gastroesophageal Junction Adenocarcinoma
zolbetuximab-clzb
Sensitive: C3 – Early Trials
zolbetuximab-clzb
Sensitive
:
C3
zolbetuximab-clzb
Sensitive: C3 – Early Trials
zolbetuximab-clzb
Sensitive
:
C3
CLDN18.2 overexpression
Gastric Cancer
CLDN18.2 overexpression
Gastric Cancer
zolbetuximab-clzb
Sensitive: C3 – Early Trials
zolbetuximab-clzb
Sensitive
:
C3
zolbetuximab-clzb
Sensitive: C3 – Early Trials
zolbetuximab-clzb
Sensitive
:
C3
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
Q-1802
Sensitive: C3 – Early Trials
Q-1802
Sensitive
:
C3
Q-1802
Sensitive: C3 – Early Trials
Q-1802
Sensitive
:
C3
CLDN18.2 overexpression
Gastric Cancer
CLDN18.2 overexpression
Gastric Cancer
TST001
Sensitive: C3 – Early Trials
TST001
Sensitive
:
C3
TST001
Sensitive: C3 – Early Trials
TST001
Sensitive
:
C3
CLDN18.2 overexpression
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 overexpression
Gastroesophageal Junction Adenocarcinoma
TST001
Sensitive: C3 – Early Trials
TST001
Sensitive
:
C3
TST001
Sensitive: C3 – Early Trials
TST001
Sensitive
:
C3
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
AB011
Sensitive: C3 – Early Trials
AB011
Sensitive
:
C3
AB011
Sensitive: C3 – Early Trials
AB011
Sensitive
:
C3
CLDN18.2 positive
Pancreatic Cancer
CLDN18.2 positive
Pancreatic Cancer
ZL-1211
Sensitive: C3 – Early Trials
ZL-1211
Sensitive
:
C3
ZL-1211
Sensitive: C3 – Early Trials
ZL-1211
Sensitive
:
C3
CLDN18.2 positive
Gastric Adenocarcinoma
CLDN18.2 positive
Gastric Adenocarcinoma
zolbetuximab-clzb
Sensitive: C3 – Early Trials
zolbetuximab-clzb
Sensitive
:
C3
zolbetuximab-clzb
Sensitive: C3 – Early Trials
zolbetuximab-clzb
Sensitive
:
C3
CLDN18.2 expression
Gastroesophageal Cancer
CLDN18.2 expression
Gastroesophageal Cancer
TJ-CD4B
Sensitive: C3 – Early Trials
TJ-CD4B
Sensitive
:
C3
TJ-CD4B
Sensitive: C3 – Early Trials
TJ-CD4B
Sensitive
:
C3
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
ZL-1211
Sensitive: C4 – Case Studies
ZL-1211
Sensitive
:
C4
ZL-1211
Sensitive: C4 – Case Studies
ZL-1211
Sensitive
:
C4
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
CLDN18.2 expression
Solid Tumor
CLDN18.2 expression
Solid Tumor
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
nivolumab + TJ-CD4B
Sensitive: D – Preclinical
nivolumab + TJ-CD4B
Sensitive
:
D
nivolumab + TJ-CD4B
Sensitive: D – Preclinical
nivolumab + TJ-CD4B
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login